4.7 Article

Light-controlled inhibition of malignant glioma by opsin gene transfer

Journal

CELL DEATH & DISEASE
Volume 4, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/cddis.2013.425

Keywords

gene therapy; cancer; channelrhodopsin; optogenetic; glioma

Categories

Funding

  1. National Basic Research Program of China [2012CB966902, 2010CB529605]
  2. National Natural Science Foundation of China [NSFC 81000551, 81000595, 91132306]
  3. Instrument Developing Project of the Chinese Academy of Sciences [2010019]
  4. Strategic Priority Research Program (B) of the Chinese Academy of Sciences [XDB02050003]
  5. 'Hundred Talents Program' of the Chinese Academy of Science
  6. National Key Technology Research and Development Program of the Ministry of Science and Technology of China [2012BAI01B08]
  7. Guangdong Innovation Research Team Fund for Low-cost Healthcare Technologies
  8. Shenzhen Governmental Basic Research Grant [JC201006040897A, JC201005270296A, JC201005270291A]

Ask authors/readers for more resources

Glioblastomas are aggressive cancers with low survival rates and poor prognosis because of their highly proliferative and invasive capacity. In the current study, we describe a new optogenetic strategy that selectively inhibits glioma cells through light-controlled membrane depolarization and cell death. Transfer of the engineered opsin ChETA (engineered Channelrhodopsin-2 variant) gene into primary human glioma cells or cell lines, but not normal astrocytes, unexpectedly decreased cell proliferation and increased mitochondria-dependent apoptosis, upon light stimulation. These optogenetic effects were mediated by membrane depolarization-induced reductions in cyclin expression and mitochondrial transmembrane potential. Importantly, the ChETA gene transfer and light illumination in mice significantly inhibited subcutaneous and intracranial glioma growth and increased the survival of the animals bearing the glioma. These results uncover an unexpected effect of opsin ion channels on glioma cells and offer the opportunity for the first time to treat glioma using a light-controllable optogenetic approach.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available